Clinical trials
Open Label clinical trials
Below are recruiting open label clinical trials, each written for real people, not researchers. We’re tracking 367 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07073547RecruitingPhase 1
Study of AZD0120 for multiple myeloma patients
This trial tests a new drug, AZD0120, in people with multiple myeloma. It aims to find the right dose and see how safe and effective it is. The study includes both newly diagnosed and early relapsed patients.
Phoenix, ArizonaAges 18 years+ - NCT07078682Recruiting
Study of two supplements for uterine fibroid symptoms
This trial tests two supplements (Elix Cycle Balance and Elix Daily Harmony) to see if they can reduce pain and other symptoms caused by uterine fibroids. It is for women who have regular but painful periods and want to try a non-medicine option.
Las Vegas, NevadaAges 20–45 - NCT07097701RecruitingPhase 3
Comparing two forms of mexiletine for non-dystrophic myotonias
This trial compares a new extended-release (PR) form of mexiletine to the immediate-release (IR) form in people with non-dystrophic myotonias. The goal is to see if the longer-acting version works as well or better with fewer side effects.
LeuvenAges 16 years+ - NCT07105709RecruitingPhase 2
Extension study for early Alzheimer's treatment
This study is a follow-up for people who completed a previous trial of an experimental treatment for early Alzheimer's disease. It will continue to test the treatment's safety and effects over a longer period.
Maitland, FloridaAges 50–85 - NCT07106892RecruitingPhase 2
Testing HLX43 for advanced colorectal cancer
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
BeijingAges 3 weeks–2 months - NCT07112183RecruitingPhase 4
Treprostinil study for Raynaud's attacks
This trial tests a medication called treprostinil to see if it can help people who have frequent Raynaud's attacks. It is for patients with primary or secondary Raynaud's (related to conditions like scleroderma or lupus) who still have attacks despite current treatments.
Boston, MassachusettsAges 18 years+ - NCT07120971RecruitingEarly Phase 1
Metformin study for premature babies with lung disease
This study tests whether metformin, a medicine used for diabetes, can help premature babies with chronic lung disease (bronchopulmonary dysplasia, or BPD) breathe better. It may reduce the need for breathing machines.
Milwaukee, WisconsinAges 1 week–6 months - NCT07123298Recruiting
Program to help older adults feel less alone at home
This study tests a program called CAPABLE Care + Connect that helps older adults who feel lonely or isolated and have trouble with daily activities at home. It connects them with support to feel more capable and less alone.
Baltimore, MarylandAges 50 years+ - NCT07141329RecruitingPhase 2
Long-term study of SPN-817 for focal seizures
This study gives SPN-817 to people who completed a prior study of the same drug, to see if it stays safe and works well over a longer time. You may qualify if you already finished that study and have stable seizure medicine.
Port Charlotte, FloridaAges 18 years+ - NCT07172893RecruitingPhase 4
Dermabind TL for diabetic foot ulcers
This trial tests a new wound dressing called DermaBind TL for people with diabetic foot ulcers. It aims to see if the dressing helps heal these wounds, which can be hard to treat.
DeLand, FloridaAges 18–80 - NCT07190300RecruitingPhase 1/Phase 2
Testing tulmimetostat with hormone therapy for metastatic prostate cancer
This trial tests a new drug, tulmimetostat, combined with standard hormone therapies like darolutamide or abiraterone for men with metastatic prostate cancer that still responds to hormone treatment. The goal is to see if the combination works better than standard therapy alone.
Birmingham, AlabamaAges 18 years+ - NCT07200193RecruitingPhase 1/Phase 2
Study of CRMA-1001 for chronic hepatitis B
This trial tests a new drug called CRMA-1001 in people with chronic hepatitis B who are already on antiviral therapy. The goal is to see if it can help control the virus better.
LyonAges 18–64 - NCT07202299Recruiting
Weaning preterm babies off high-frequency breathing machines
This trial tests two different ways to safely take preterm babies off a special breathing machine (HFOV). It aims to find which method works better for babies with breathing problems (respiratory distress syndrome).
Al MansurahAges Any age - NCT07207070RecruitingPhase 3
New drug combination for PIK3CA-mutated breast cancer
This trial tests a new combination of two drugs (JS105 plus dalpiciclib and fulvestrant) against a standard combination (dalpiciclib plus fulvestrant) for people whose breast cancer has a PIK3CA mutation. The goal is to see if adding JS105 helps control the cancer longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07209462RecruitingPhase 2
MRM-3379 for Fragile X Syndrome in males
This trial tests an investigational medicine called MRM-3379 in males with Fragile X syndrome. It looks at how the medicine affects thinking and behavior over time.
Phoenix, ArizonaAges 13–45 - NCT07220603RecruitingPhase 2
Long-term safety study for people with myotonic dystrophy type 1
This is a follow-up study for people with myotonic dystrophy type 1 who already received the study drug PGN-EDODM1 in an earlier trial. It lets you continue treatment and helps researchers learn more about long-term safety and effects.
Calgary, AlbertaAges Any age - NCT07228078RecruitingPhase 2
Open-label extension for Alzheimer's study completers
This trial continues treatment for people who finished the earlier SNK01-AD01 study. It tests a personalized cell therapy (SNK01) to see if ongoing treatment is safe and helpful for Alzheimer's disease.
Glendale, CaliforniaAges 40–85 - NCT07230353RecruitingPhase 1
Plamotamab for moderate to severe rheumatoid arthritis
This trial tests a new treatment called plamotamab for people with moderate to severe rheumatoid arthritis (RA) who have not had enough relief from current treatments. The goal is to see if it is safe and to help control RA symptoms.
TbilisiAges 18 years+ - NCT07233213RecruitingPhase 3
IVIG for chronic low platelet condition
This trial tests an intravenous immunoglobulin (IVIG) treatment for chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing low counts and bleeding risk. It aims to safely raise platelet levels using donated antibodies.
Ankara, AltındağAges 18–65 - NCT07238868RecruitingPhase 2
Long-term safety study of CB03-154 for epilepsy
This study is a long-term follow-up for people with epilepsy who already completed a previous trial of the drug CB03-154. It checks if the drug remains safe and effective over more time.
Melbourne, VictoriaAges 18–70 - NCT07245667RecruitingPhase 2
Tolnaftate stick for athlete's foot study
This trial tests a medicated stick for athlete's foot (tinea pedis). It aims to see if the treatment is safe and works well.
Framingham, MassachusettsAges 16 years+ - NCT06194799Enrolling by invitationPhase 3
Long-term ACP-204 for Alzheimer's psychosis
This study tests a long-term medicine (ACP-204) for people with Alzheimer's disease who also have psychosis (hallucinations or delusions). If you took part in the earlier ACP-204 study, this open-label extension lets you continue receiving the medicine to see how well it works over time.
Costa Mesa, CaliforniaAges 55–95 - NCT07251608RecruitingPhase 1
Safety study of Niagen injections for fatigue
This trial tests whether Niagen injections are safe for people who feel tired. You would inject the study drug yourself at home for about three months.
Miami, FloridaAges 18 years+ - NCT07256301RecruitingPhase 1
Testing EA5 in adults with paroxysmal nocturnal hemoglobinuria (PNH)
This clinical trial tests an investigational drug called EA5 for people with PNH, a rare blood disease where red blood cells break down too quickly. It is for adults who either have never taken a complement inhibitor or stopped taking one recently, and who still have signs or symptoms of PNH.
Tianjin, Tianjin MunicipalityAges 18 years+
Hear when a new Open Label trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for open label?
- Yes. Clin2 currently lists 367 recruiting open label studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a open label trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a open label trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.